Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.
Company (Alive / Active)
141, President-Kennedy Ave.
Montreal, H2X 1Y4
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)
|Antibodies against kidney associated antigen 1 and antigen binding fragments thereof||Apr 25, 2016||Nov 28, 2017||Patent|
|Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer||Feb 22, 2013||Nov 21, 2017||Patent|
|Polynucleotides and polypeptide sequences involved in the process of bone remodeling||Apr 20, 2015||Jul 04, 2017||Patent|
|Siglec-15 antibodies in treating bone loss-related disease||Apr 25, 2016||Apr 11, 2017||Patent|
|Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume||Jun 23, 2014||Dec 06, 2016||Patent|